Connect with us

Hi, what are you looking for?

Jewish Business News

StartUps

Teva Announces Approval Of Generic Breast Cancer, Osteoporosis Drug Evista Tablets In The US

Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
images

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the approval from the US Food and Drug Administration (FDA) to market the generic equivalent to Evista (Raloxifene) Tablets, 60 mg, in the United States.

Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Teva will begin shipping the product within the next 30 days.

Evista 60 mg Tablets marketed by Eli Lilly and Company, had annual sales of approximately $824 million in the United States, according to IMS data as of December 2013.

 

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Newsletter

Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

empty

The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Advertisement
cialis cialis satış